3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
251
Lymphoma
241
Precursor Cell Lymphoblastic Leukemia-Lymphoma
192
Leukemia
178
Lymphoma, Large B-Cell, Diffuse
167
Multiple Myeloma
166
Lymphoma, Non-Hodgkin
155
Leukemia, Lymphocytic, Chronic, B-Cell
146
Leukemia, Myeloid, Acute
136
Myelodysplastic Syndromes
116
Hodgkin Disease
115
Lymphoma, Follicular
113
Burkitt Lymphoma
108
Lymphoma, Mantle-Cell
104
Lymphoma, B-Cell, Marginal Zone
76
Lymphoma, Large-Cell, Immunoblastic
64
Neoplasms, Plasma Cell
59
Recurrence
58
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
57
Myeloproliferative Disorders
53
Neoplasms
49
Leukemia, Myeloid, Chronic-Phase
49
Triple Negative Breast Neoplasms
47
Leukemia, Myeloid, Accelerated Phase
47
Melanoma
46
Leukemia, Myelomonocytic, Chronic
46
Dendritic Cell Sarcoma, Interdigitating
46
Waldenstrom Macroglobulinemia
42
Hematologic Neoplasms
41
Congenital Abnormalities
39
Interventions
Radiotherapy
1
Paclitaxel
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prosthesis Failure
×
Cyclophosphamide
×
Clear all
NCT01918124
2018-10-12
EC-0701
Fudan University
Phase 2
Completed
80 enrolled